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heparinization in cardiac surgery. The modern heparin-
coated cardiopulmonary bypass (CPB) equipment has
gained much interest, not only because of its anticoag-
ulatory properties, but also because it inhibits activation
of many inflammatory systems, for example, comple-
H eparin-coating of foreign surfaces for use in extra-corporeal circulation was introduced more than 30
years ago to reduce the need for systemic anticoagu-
lants. Such reduction is now feasible, but there is still
controversy concerning the safety of reduced systemic
Objective: Our objective was to study mechanisms for reduced comple-
ment activation by heparin coating of cardiopulmonary bypass equip-
ment in clinical heart surgery. Methods: Adults undergoing elective coro-
nary artery bypass grafting were randomized to cardiopulmonary
bypass with Duraflo II heparin-coated (n = 15) or uncoated (n = 14) sets
(Duraflo coating surface; Baxter International, Inc, Deerfield, Ill).
Blood samples were analyzed with the use of enzyme immunoassays for
C1rs-C1 inhibitor complexes and the activation products Bb, C4bc,
C3bc, C5a-desArg, and the terminal complement complex. Data were
compared by repeated-measures analysis of variance. Results: C1 was
activated during bypass, and increases in C1rs-C1 inhibitor complexes
were larger with heparin coating (P = .03). C4bc increased after admin-
istration of protamine, without intergroup differences (P = .69). Bb (P =
.22) and C5a-desArg (P = .13) tended to increase less with heparin coat-
ing. Formation of C3bc (P = .03) and the terminal complement complex
(P < .01) was significantly reduced with heparin coating. C5a-desArg
increased 2-fold during bypass, whereas the terminal complement com-
plex increased 10- to 20-fold. Maximal terminal complement complex
concentrations were significantly correlated to maximal Bb and C3bc (R
= 0.6, P < .001), but not to C1rs-C1 inhibitor complexes or C4bc (R <
0.05, P > .8). Conclusions: C1 activation during bypass was increased by
heparin coating, but further classical pathway activation was held in
check until administration of protamine. Heparin coating significantly
inhibited C3bc and terminal complement complex formation. Terminal
complement complex concentrations were related to alternative path-
way activation and may be useful for evaluation of differences in bypass
circuitry. Increases and intergroup differences in terminal complement
complex concentrations were much larger than those in C5a-desArg. (J
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ment, granulocytes, and platelets.1-3 The mechanisms
for these anti-inflammatory effects of heparin coating
are largely unknown.
Initiation of complement activation may take place
via three pathways (Fig 1). In the classical pathway,
binding of factor C1q to antigen-antibody complexes,
aggregated immunoglobulins, or certain other sub-
stances activates a series of reactions leading to forma-
tion of the classical pathway C3 convertase. C1
inhibitor is the main regulatory protein of the initial
reaction in this pathway. In the lectin pathway, binding
of circulating lectin-binding proteins to carbohydrates
on surfaces of pathogens leads to formation of a simi-
lar C3 convertase. Finally, a host of non-self surfaces
on pathogens or foreign substances such as plastics in
heart-lung machines activate factor B of the alternative
pathway, leading to formation of the alternative path-
way C3 convertase. Classical activation may also initi-
ate the alternative pathway, amplifying C3 convertase
formation.
Irrespective of initial pathway, the subsequent steps
of complement activation are the same. C3b fragments
formed by the C3 convertases participates in formation
of a C5 convertase, and C5b fragments from C5 cleav-
age bind factors C6, C7, C8, and C9 to form the termi-
nal complement complex (TCC). TCC exists in a mem-
branebound form, C5b-9(m), and a form circulating in
plasma (SC5b-9) bound to the regulatory proteins vit-
ronectin and clusterin.
The present study was performed to gain further
insight into possible mechanisms for complement inhi-
bition by heparin coating in clinical heart surgery, by
studying markers of activation at various levels of the
cascade.
Patients and methods
Twenty-nine adult patients admitted for elective coronary
bypass surgery at the National Hospital were included in the
study after giving informed consent. Half of the patients were
randomly chosen from each of the two groups of participants
in a larger study of complications after CPB, which is pre-
sented elsewhere.4 Exclusion criteria for the present study
were left ventricular ejection fraction less than 0.40, ongoing
infections, liver failure, other major noncardiac illness, or use
of steroids or nonsteroid anti-inflammatory agents except
acetylsalicylic acid.
As part of the larger study, the patients had been randomly
assigned to CPB with one of the following setups:
• Heparin-coated group (n = 15): Univox oxygenator and
tubing/connectors, cardiotomy suction and a 25-mm arterial
line screen filter (Bentley/Baxter, Uden, The Netherlands)
with the entire blood-contact surface heparin-coated by the
Duraflo II method (ionically bound heparin) (Baxter
International, Inc, Deerfield, Ill)
• Uncoated group (n = 14): Uncoated, otherwise similar oxy-
genator, tubing, and filter set
The extracorporeal circuit was primed with 1800 mL
Ringer’s acetate containing 5000 IU heparin. Before CPB,
300 IU heparin per kilogram of body weight was adminis-
tered intravenously in both groups. Additional heparin was
given if needed to maintain an activated clotting time of 480
seconds or more. Cardiotomy suction and a nonpulsatile
roller pump were used in all patients. Cold St Thomas’
Hospital cardioplegic solution was used in addition to local
cooling and moderate general hypothermia (30°C-32°C).
After CPB, 1 mg protamine was administered for each 100
IU heparin. Additional protamine was given if necessary to
re-establish the preoperative activated clotting time.
The number of grafts and duration of the operation, CPB,
and aortic occlusion were noted.
Blood samples and analyses. Samples anticoagulated
with ethylenediaminetetraacetic acid were obtained just
before systemic heparinization, after 30 minutes of CPB, at
termination of CPB, during closure of the skin over the ster-
num, and 3 hours after the operation. The exact sampling
times were recorded. So that in vitro activation could be
avoided, the tubes were kept on ice until centrifugation with-
in 8 hours, and plasma was stored at –70°C.5
Hemoglobin, hematocrit, and blood cell counts were deter-
mined in an automated analyzer (Technicon H-l, Miles,
Tarrytown, NY).
Complexes between C1 inhibitor and C1r and C1s (C1rs-
C1inh) were measured in an enzyme immunoassay (EIA)
specific for a neoepitope exposed in C1 inhibitor when com-
plexed to its proteases, using a mixture of anti-C1r and anti-
C1s antibodies in the second step.6 C1rs-C1inh is formed
during the first activation steps in the classical complement
pathway.
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Fig 1. Simplified overview of the complement cascade.
C4bC2a and C3bBb are the classical and alternative C3 con-
vertases, respectively. C4aC2aC3b and C3bBbC3b are the
corresponding classical and alternative C5 convertases. See
text for further details.
C4 activation products (C4bc) were quantitated in an EIA7
specific for a neoepitope expressed on C4b, iC4b, and C4c,
but not on native C4. C4bc is formed at a later stage during
classical pathway activation than C1rs-C1inh. The mono-
clonal C4 and C1 inhibitor antibodies were a kind gift from
Professor C. E. Hack, Amsterdam, The Netherlands.
Factor B activation was measured by a Bb kit (Quidel, San
Diego, Calif) according to the manufacturer’s instructions.
Bb is formed during activation of the alternative complement
pathway.
C3 activation products (C3bc) were measured in an EIA7
specific for a neoepitope expressed on C3b, iC3b, and C3c,
but not on native C3. C3bc is formed on activation of either
the classical or the alternative pathway.
C5a-desArg was analyzed in a neoepitope-specific sand-
wich EIA as earlier described.8
The TCC was determined in an EIA7 specific for a C9
neoepitope.
Zymosan-activated serum, defined as containing 1000 arbi-
trary units per milliliter (AU/mL), was used as standard in the
C3bc and TCC assays, because use of SI units requires that the
neoepitope be confined to one particular molecule with a
defined molecular weight.7 Likewise for the C4bc and the
C1rs-C1inh assays, normal human serum activated through
the classical pathway using heat aggregated immunoglobulins
and defined to contain 1000 AU/mL was used as standard.7
The results were corrected for hemodilution with the use of
the hematocrit value.9
Statistics. Data are presented as medians with 95% non-
parametric confidence intervals based on Walsh numbers. All
variables were first analyzed by 2-way analysis of variance
(ANOVA) for repeated measures, using the SPSS program
package (SPSS, Inc, Chicago, Ill). Because of non-normal
variables and unequal variances, the conditions for such test-
ing were only partly met. Therefore changes by time within
each group were subsequently studied by the Friedman test
and intergroup differences by the Mann-Whitney U test. The
P values from ANOVA were used as criteria for the smallest
significant P values in the subsequent Friedman and Mann-
Whitney tests. The conclusions from the ANOVA were unal-
tered if performed on rank transformed data. Maximal con-
centrations for each patient irrespective of time of occurrence
were compared between the two groups by the Mann-
Whitney U test, and Pearson’s correlation coefficients
between maximal concentrations of the various complement
activation parameters were calculated.
The study was approved by the regional ethical committee
on February 25, 1993.
Results
Patient characteristics and variables pertaining to the
operation are given in Table I. There were no signifi-
cant intergroup differences with respect to these vari-
ables or with respect to sampling time points.
C1rs-C1inh. C1rs-C1inh concentrations increased
significantly by time in both groups (P < .01), and the
concentrations were significantly higher in the heparin-
coated group after 30 minutes of CPB and at termina-
tion of CPB (P < .05) (Fig 2, A). The C1rs-C1inh com-
plex concentration was maximal at 30 minutes of CPB
in 2 patients, at termination of CPB in 11 patients, at
closure in 9 patients, and 3 hours after the operation in
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Table I. Patient characteristics and variables pertaining
to operation
Uncoated Heparin-coated 
group group P value
Gender (F/M) 1/13 1/14 .96
Age (y) 63 (58-67) 63 (57-66) .98
No. of grafts 3.0 (3.0-3.5) 3.0 (2.5-3.5) .57
Aortic occlusion (min) 31 (27-35) 31 (22-29) .81
CPB duration (min) 65 (58-74) 65 (54-76) .95
Operation time (min) 93 (86-103) 100 (84-114) .84
Fig 2. Classical complement activation (median and 95%
confidence intervals) by median sampling times in patients
undergoing aorta-coronary bypass operations with (n = 15)
and without (n = 14) Duraflo II heparin-coated CPB circuits.
A, Plasma concentrations of C1rs-C1 inhibitor complexes.
Groups were significantly different (P = .03, ANOVA). B,
Plasma concentrations of C4 activation products (C4bc).
Groups were not significantly different (P = .69, ANOVA).
A
B
the remaining 7 patients. The maximal concentration
was significantly higher in the heparin-coated group
(uncoated, 44 AU/mL [37-53 AU/mL]; heparin-coated,
61 AU/mL [48-78 AU/mL]; P < .05).
C4bc. C4bc concentrations increased significantly
after termination of CPB (P = .01) (Fig 2, B). There
were no significant intergroup differences (P = .69).
The C4bc maximum occurred after 30 minutes of CPB
in 2 patients, at closure of the wound in 21 patients, and
3 hours after the operation in 6 patients. The maximal
concentrations were 35 AU/mL (26-49 AU/mL) in the
uncoated group and 37 AU/mL (25-51 AU/mL) in the
heparin-coated group (P = .86). Bb increased signifi-
cantly during CPB (P < .001), but there were no sig-
nificant intergroup differences (P = .22) (Fig 3). The
Bb concentration reached a maximum after 30 minutes
of CPB in 2 patients, at termination of CPB in 14
patients, at closure of the wound in 11 patients, and 3
hours after the operation in 1 patient. The maximal
concentration was 7.2 m g/mL (6.2-8.2 m g/mL) in the
uncoated group and 6.4 m g/mL (5.5-7.5 m g/mL) in the
heparin-coated group (P = .29).
C3bc. C3bc concentrations increased by time until
closure of the skin over sternum (P < .01) (Fig 4). The
C3bc concentrations were significantly lower in the
heparin-coated group after 30 minutes of CPB and at
termination of CPB (P < .01). C3bc reached its maxi-
mum at termination of CPB in 7 patients, at closure of
the wound in 21 patients, and 3 hours after the opera-
tion in 1 patient. Maximal concentrations were 131
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Fig 3. Plasma concentrations of activated factor B (Bb)
(median and 95% confidence intervals) by median sampling
times in patients undergoing aorta-coronary bypass opera-
tions with (n = 15) and without (n = 14) Duraflo II heparin-
coated CPB circuits. Groups were not significantly different
(P = .22, ANOVA).
Fig 4. Plasma concentrations of C3 activation products
(C3bc) (median and 95% confidence intervals) by median
sampling times in patients undergoing aorta-coronary bypass
operations with (n = 15) and without (n = 14) Duraflo II
heparin-coated CPB circuits. Groups were significantly dif-
ferent (P = .03, ANOVA).
Fig 5. Terminal complement activation (median and 95%
confidence intervals) by median sampling times in patients
undergoing aorta-coronary bypass operations with (n = 15)
and without (n = 14) Duraflo II heparin-coated CPB circuits.
A, Plasma concentrations of C5a-desArg. Groups were not
significantly different (P = .13, ANOVA). B, Plasma concen-
trations of the TCC. Groups were significantly different (P
=.004, ANOVA).
A
B
AU/mL (104-173 AU/mL) in the uncoated group and
82 AU/mL (64-116 AU/mL) in the heparin-coated
group (P = .01).
C5a-desArg. C5a-desArg concentrations increased
significantly after onset of CPB (P < .01) (Fig 5, A).
There were no significant differences in C5a-desArg
concentrations between the groups, even if concentra-
tions tended to be lower in the heparin-coated group (P
= .13).
TCC. TCC formation was significant until termina-
tion of CPB (P < .001) (Fig 5, B). The TCC concentra-
tions were significantly lower in the heparin-coated
group after 30 minutes of CPB (P < .01), at termination
of CPB (P < .001), and at closure of the wound over the
sternum (P < .05). The maximal TCC concentration
was found at termination of CPB in 22 patients and at
closure of the wound in the remaining 7 patients.
Maximal TCC concentrations were 10.4 AU/mL (7.1-
13.8 AU/mL) in the uncoated group and 5.1 AU/mL
(3.8-7.0 AU/mL) in the heparin-coated group (P <
.001).
The correlation coefficients between the maximal
concentrations of the complement activation parame-
ters are given in Table II. The markers of classical acti-
vation (C1rs-C1inh and C4bc) were significantly corre-
lated. TCC was significantly correlated with Bb, C3bc,
and C5a-desArg.
Discussion
Classical and alternative pathway activation. Our
data on C1rs-C1inh confirm that the classical pathway
is activated during CPB, as shown by others.10 The
finding of increased formation of C1rs-C1inh complex-
es after heparin coating may seem paradoxic. However,
it is in keeping with the observation that heparin-coat-
ed polystyrene microtiter plates selectively bound C1q
on incubation with human serum or plasma.11 During
CPB, this increased C1 activation was apparently held
in check by C1 inhibitor–mediated inactivation,
because C4bc did not increase in parallel with C1rs-
C1inh. In vitro, heparin is an inhibitor of C1-mediated
hemolysis by potentiation of C1 inhibitor,12 and our
data support that such C1 inhibitor potentiation may
take place in vivo as well. This may explain the appar-
ent discrepancy with two other recent studies on com-
plement inhibition by heparin coating13,14 failing to
show classical pathway activation as measured by
C4bc only.
C4 activation was substantial after termination of
CPB, probably as a consequence of the formation of
circulating heparin-protamine complexes.15 Thus max-
imal concentrations of C1rs-C1inh were significantly
correlated to maximal concentrations of C4bc, even if
the time course for formation was different.
Taken together, these findings indicate efficient inhi-
bition after C1 activation during CPB, but not after
administration of protamine. The importance of such
C1 inhibitor–mediated classical pathway inhibition
during CPB is underscored by the substantial increase
in classical activation found in a patient with C1
inhibitor insufficiency.16
As expected, there was significant activation of the
alternative pathway during CPB, as reflected in the Bb
concentrations (Fig 3). Even if the Bb concentration
tended to be lower in the heparin-coated group, activa-
tion of the alternative pathway was not significantly
influenced by heparin coating, but the study was small.
Heparin-protamine complexes are activators of the
classical complement pathway.15 The C4 activation
related to protamine administration was followed by
increased formation of C3bc in 22 of the 29 patients.
However, in only 7 patients did we detect an increase in
TCC after administration of protamine, indicating that
the C3 convertase formed might not be very efficient or
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Table II. Correlation among complement activation parameters*
C4bc Bb C3bc C5a-desArg TCC
C1rs-C1inh R = 0.50 R = 0.29 R = 0.25 R = 0.17 R = 0.05
P = .006 P = .12 P = .20 P = .38 P = .79
C4bc R = .06 R = 0.25 R = 0.09 R = 0.03
P = .76 P = .19 P = .65 P = .86
Bb R = 0.32 R = 0.30 R = 0.66
P = .09 P = .11 P < .001
C3bc R = 0.61 R = 0.65
P < .001 P < .001
C5a-desArg R = 0.54
P = .003
Significant correlations are given in boldface type.
*Maximal concentration for each patient irrespective of sampling point.
that some form of inhibition occurs during the subse-
quent assembly of TCC. This is in keeping with previ-
ous observations of a relative inefficiency of terminal
complement activation compared with C3 cleavage in
vitro.17 We may speculate that the C5 convertase
formed by alternative pathway activation is more effi-
cient than that formed by classical pathway activation.
There was significant correlation between TCC and
the alternative pathway markers Bb and C3bc, but not
between TCC and the classical pathway markers C1rs-
C1inh and C4bc. This finding supports the hypothesis
that TCC formation in cardiac surgery is more closely
related to alternative pathway activation than classical
pathway activation. Thus TCC may be more an indica-
tor of factors connected to the oxygenator and other
parts of the CPB circuit and less sensitive to differences
in heparin-protamine regimens, which would be an
advantage in studies of biocompatibility. 
Inhibition of C3 activation and TCC formation by
heparin coating. As previously shown by us and oth-
ers,1,13 heparin coating substantially reduced the for-
mation of C3 activation products and TCC. In the men-
tioned study on complement activation by microtiter
plates,11 bound C3b was more rapidly converted to
iC3b after heparin coating, indicating more sufficient
factor I–mediated and/or factor H–mediated inhibition
of C3 activation. A potentiating effect of heparin on
factor H has been demonstrated.18 Heparin may also
inhibit formation of the C3 convertase C3bBb by bind-
ing to C3b at the site for factor B.19 These mechanisms
may explain the reduced formation of C3 activation
products in the present study.
The reduced formation of TCC after heparin coating
is a natural consequence of reduced C3 activation.
However, the reduction of maximal TCC concentra-
tions by heparin coating was relatively larger than that
of maximal C3bc concentrations, indicating that the
surface-bound heparin might directly influence the for-
mation of TCC during CPB. In vitro, heparin inhibited
formation of the C5b67 complex, which is one of the
steps in TCC formation,20 and we may hypothesize that
such an effect takes place in vivo as well. Furthermore,
heparin may bind fluid-phase TCC via S-protein (vit-
ronectin) in such complexes.21 Because we did not
measure surface-bound complement factors, we do not
know whether binding of TCC to the heparin coating
contributed to the reduced amounts in plasma. This
seems unlikely, however, because virtually no binding
of TCC to another heparin-coated surface was found in
vitro.22
Measurement of terminal complement activation.
This study included measurement of both plasma C5a-
desArg and TCC as indicators of terminal (C5-C9) acti-
vation. Both were significantly correlated with C3bc
(Table II). Even if C5a-desArg concentrations were
slightly lower in the heparin-coated group, the differ-
ences were not significant despite the significant reduc-
tions in both C3bc and TCC. Rapid binding of C5a-
desArg to leukocytes may explain this apparent
contradiction. Furthermore, the study was small. In a
previous investigation, C5a-desArg formation was com-
pletely abolished with heparin coating in model CPB
with recirculation of human blood, but no differences
were found between 10 patients operated on with
uncoated CPB equipment and 10 patients operated on
with heparin-coated CPB sets.23
TCC has been a good discriminator of complement
activation differences in vitro.24 The usefulness of TCC
may be due to the very low baseline concentrations
combined with large increases during complement acti-
vation: approximately 10-fold to 20-fold in the present
study. C5a-desArg increases, on the other hand, were
about 2-fold, and C3bc increases were approximately
3-fold to 4-fold. These figures may explain why C5a-
desArg differences between the groups were not signif-
icant, C3bc differences were moderately significant,
and TCC differences were highly significant. Simul-
taneous measurement of cell-bound and circulating
C5a-desArg may increase the sensitivity for discrimi-
nation of complement activation differences,25 but this
approach is more time consuming. Quantitation of
plasma TCC, which has a half-life of approximately 50
minutes,26 is probably the best marker of TCC activa-
tion available at present.
We are grateful to Grethe Bergseth, Bente Falang, Hilde
Fure, and Kirsti Løseth for excellent assistance with the com-
plement assays.
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